New study highlights bone density benefits of denosumab

A drug called denosumab increases bone mineral density and decreases bone turnover in women – great news for those at high risk of fractures, says research published in Osteoporosis.
Canadian scientists divided 17,000 women aged 55 years or older who had failed to benefit from treatment with bisphosphonates due to issues with adherence into two groups.
One group was given an injection of denosumab (60mg) every six months. The others took 150mg of an oral bisphosphonate (ibandronate or risedronate) every month for one year.
Denosumab was associated with greater gains in bone mineral density in the hip, femoral neck and lumbar spine at 12 months than the monthly oral bisphosphonates, both in the overall population and in those at high-risk. And denosumab led to greater decreases in bone turnover too.